Clarus’ Oral Testosterone’s Perceived Advantage Becomes Downfall At FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral dosing is “double-edge sword” as unique concerns with Rextoro’s formulation leads to negative advisory committee vote for the testosterone replacement treatment despite panelists’ desire for an oral option.
You may also be interested in...
Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia
The latest drug development news and highlights from our US FDA Performance Tracker.
Surprise Approval For Clarus' Oral Testosterone Includes Black Box, No REMS
Jatenzo clears US FDA 15 months after second negative advisory committee review.
US FDA Approval Climate: What Do The Oral Testosterone Reviews Tell Us?
Second go-round for oral testosterone could have marked new boundary on how far FDA is willing to go in approving new entrants to a market with widespread historic off-label use and CV risks.